PharmaFocus Today – Page 3 – media

AideaPharmaceuticals plans to raise no more than 1.277 billion yuan through a private placement to focus on the global clinical development of innovative HIV drugs

On the evening of March 2nd, AideaPharmaceutical…The company announced that it plans to raise no more than RMB 1.277 billion through a private placement of shares. The funds will be invested in three main areas: RMB 767 million for the global clinical development of a novel HIV integrase inhibitor; RMB 130 million for the acquisition of a 22.23% minority stake in Nanda Pharmaceutical; and RMB 380 million to supplement working capital. Fu Heliang, one of the company’s actual controllers and chairman, plans to subscribe for RMB 30 million to RMB 50 million of the issued shares. AideaPharmaceuticals , as an innovative anti-HIV drug manufacturer in ChinaAs a leading company, it has already launched two Class 1 innovative drugs in China : Enovilin and Enovitil. Currently, integrase inhibitors have become one of the mainstream treatment options for HIV/AIDS globally. In China, there are currently no independently developed innovative HIV integrase inhibitors ...
- Source: drugdu
- 48
- March 3, 2026
Giant Exits! Its Star Business Acquired

According to recent foreign media reports, Quantum Surgical has completed its acquisition of NeuWave Medical, a Johnson & Johnson subsidiary. Financial details of the transaction have not yet been disclosed. Furthermore, it is worth noting that the two companies will become subsidiaries of the newly formed holding company, Precision IO Group Inc.According to Johnson & Johnson, NeuWave Medical is a leading provider of interventional oncology solutions in the United States, and was acquired by Johnson & Johnson in 2016. According to data from PharmNet Medical Devices, NeuWave currently has 14 products on the market in the United States , including the Certus air-cooled microwave ablation device and disposable microwave ablation needles, primarily used for image-guided tumor ablation therapy. In 2020, NeuWave Medical officially entered China, and currently has two products on the market in China : a microwave ablation therapy device and a disposable microwave ablation puncture needle. In 2025, ...
- Source: drugdu
- 41
- March 3, 2026
Focusing on cardiovascular and cerebrovascular diseases! OpenMediLead Medical Intelligence Dual Engines Launch Internal Testing, Connecting Drug Development and Clinical Diagnosis in a Closed Loop

Recently, the OpenMediLead platform, focusing on the cardiovascular and cerebrovascular field, officially entered its internal testing phase on WeChat mini-program. The platform centers on the interactive testing of its AI drug discovery engine and AI clinical diagnostic decision-making engine. Utilizing a lightweight mini-program entry point, it conducts real-world scenario verification and collects user feedback, laying a crucial foundation for the next step of officially establishing a closed-loop system between clinical practice and research. It aims to reconstruct a new model of medical and pharmaceutical integration using artificial intelligence technology, facilitating precise diagnosis and treatment of cardiovascular and cerebrovascular diseases and the efficient development of innovative drugs. OpenMediLead was founded by Li Chengli and his core team. The platform has a clear and firm core value: with the vision of “building an ecosystem of artificial intelligence in medicine and pharmaceuticals”, and the mission of “making medical knowledge and pharmaceuticals less difficult ...
- Source: drugdu
- 37
- March 3, 2026
Innovent Biologics Announces Approval of New Indication for BTK Inhibitor “Pitubrutinib” in China

On March 2, Innovent Biologics and Eli Lilly and Company China jointly announced that the non-covalent (reversible) BTK inhibitor Japalli® (pitubrutinib) has been officially approved by the National Medical Products Administration (NMPA) of China for a new indication: the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have previously received at least one systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Pitobrutinib is a highly selective kinase inhibitor with a novel binding mechanism that can re-establish BTK inhibition in CLL/SLL patients who have previously received covalent BTK inhibitors (including ibrutinib, acomitinib, zanubrutinib, or orelabrutinib), thus prolonging the benefits of targeting the BTK pathway. Pitobrutinib, as a non-covalent (reversible) BTK inhibitor, was approved by the US FDA in January 2023. In October 2024, pitotubactinib was approved in China as monotherapy for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at ...
- Source: drugdu
- 40
- March 3, 2026
Huadong Medicine’s subsidiary, Daer Bio, has received IND approval in China for its DR30206 injection in combination with chemotherapy for the treatment of non-small cell lung cancer

Recently, Zhejiang Daer Biotechnology Co., Ltd. (hereinafter referred to as “Daer Biotechnology”), a holding subsidiary of Huadong Medicine Co., Ltd. (hereinafter referred to as “the Company”), received the “Drug Clinical Trial Approval Notice” (Notice No.: 2026LP00516) issued by the National Medical Products Administration (NMPA). The clinical trial application for DR30206 for injection submitted by Daer Biotechnology was approved, with the indication being: this product in combination with standard chemotherapy, intended for patients with locally advanced or metastatic non-small cell lung cancer. DR30206 for injection is a Class 1 therapeutic biological product independently developed by Daer Biotech and possessing global intellectual property rights. DR30206 is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β; it restores the proliferation of exhausted CD8+ T cells by blocking the PD-1/PD-L1 signaling pathway; and reduces tumor angiogenesis and relieves immunosuppression by specifically binding to free VEGF and TGF-β, thereby achieving the goal of treating tumors. ...
- Source: drugdu
- 41
- March 3, 2026
API Is Not Just a Cost – It’s Your Ticket to Global Markets

How serious buyers actually screen suppliers For professional buyers, a complete COA and a clear GMP certificate set often carry more weight than the numbers on a quotation sheet. In many export projects, Active Pharmaceutical Ingredients (APIs) are still treated as “standard items”: available stock, basic documents, acceptable price – and the box is ticked. However, Drugdu.com’s trade data show a clear divide: suppliers that consistently receive high-quality inquiries and progress into registration and tender stages are the ones that treat APIs as the first piece of the supply chain, not just a cost element. When global buyers evaluate a new project, this is usually where they start. 01. Why is the API the “first piece”? The API is the source of pharmacological activity, but its role in regulatory and commercial decision-making is much broader. Each API comes with a full “identity profile”: CAS number, molecular structure, purity, impurity profile, ...
- Source: drugdu
- 46
- March 3, 2026
Rovaxitinib approved for marketing, filling the demand for myelofibrosis treatment

On March 2, China Biopharmaceutical (01177) issued an announcement stating that the group’s independently developed Class 1 innovative drug…Rovaxitinib tablets (trade name: Anxu®) have been approved for marketing by the National Medical Products Administration (NMPA) of China for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). In a multicenter, randomized, double-blind, double-dummy, positive-drug parallel-controlled phase II clinical trial, rovaxitinib demonstrated superior efficacy and good safety compared to hydroxyurea in the treatment of intermediate-2 and high-risk myelofibrosis patients. The results showed that in the rovaxitinib group, 58.33% of subjects achieved a spleen volume reduction of ≥35% from baseline (SVR35) at week 24, 63.89% achieved SVR35 at any time point, the mean duration of SVR35 was as long as 8.31 months, and the best total symptom score improvement of ≥50% (TSS50) rate was as high as 77.78%. The ...
- Source: drugdu
- 47
- March 2, 2026
Warrant Pharmaceuticals’ active pharmaceutical ingredient receives Brazil’s first official GMP certification

Warrant Pharmaceuticalsraw materialsAnother piece of good news for our business segment. Recently, our wholly-owned subsidiary, Hunan Huana Pharmaceutical Chiral Drugs Co., Ltd., received a Good Manufacturing Practice (GMP) certification from the Brazilian National Health Surveillance Agency (ANVISA). This marks the first time our API (Active Pharmaceutical Ingredient ) business segment has passed an official audit in Brazil, signifying that our quality management and production systems continue to meet high international standards and laying a solid foundation for further expansion into the international market. The product undergoing official audit in Brazil is fosfomycin tromethamine. It is the raw material for fosfomycin tromethamine powder and other formulations, which are mainly used to treat acute uncomplicated urinary tract infections and asymptomatic bacteriuria caused by susceptible Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter spp., Enterobacter spp., and Proteus mirabilis. During the five-day inspection, Brazilian auditing officials conducted a comprehensive audit of the company’s active ...
- Source: drugdu
- 45
- March 2, 2026
Merck’s New Story

Merck has made a change, recently announcing adjustments to its pharmaceutical business organizational structure and confirming a new head of the business. This organizational restructuring, ostensibly a rearrangement of business lines, is actually aimed at addressing the impending patent cliff for Keytruda and defending its position as the leading oncology drug. 01 Announcement of important adjustments Originally, Merck’s organizational structure was divided into two main segments: human health (i.e., pharmaceutical business) and animal health. The human health business included nine sub-segments: oncology, vaccines, hospital emergency care, cardiovascular, metabolic and respiratory, virology, neuroscience, immunology, metabolism, and others. Merck has now restructured its human health business, consolidating its previously fragmented business lines into two strategic clusters: Oncology and Specialty (Specialty Drugs), and General Drugs and Infectious Diseases. This signifies that Merck is reshaping its market competitiveness through resource focus and synergistic effects. This new round of organizational restructuring marks a new stage ...
- Source: drugdu
- 39
- March 2, 2026
Rongchang Biotechnology has turned a profit!

Recently, Rongchang Biotechnology released its preliminary financial results for 2025. Annual revenue reached 3.25 billion yuan, an increase of 89.36% year-on-year; net profit attributable to owners of the parent company was 710 million yuan, a turnaround from a loss of 1.468 billion yuan in 2024. Rongchang Bio stated that the significant year-on-year increase in the company’s operating revenue was mainly due to the increased domestic sales volume and revenue of its core products, Telitacicept and Vidicetumab , which became the core growth engine for its performance. At the same time, the company successfully reached a major cooperation agreement , resulting in a significant increase in technology licensing revenue. In June 2025, Rongchang Bio granted Telitacicept a paid license to Vor Bio. Under the agreement, Rongchang Bio will receive $125 million in cash and warrants from Vor Bio (including a $45 million upfront payment and $80 million in warrants, representing approximately ...
- Source: drugdu
- 36
- March 2, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.